We are live on ! Find out more
SOCM

SR One Capital Management Portfolio holdings

AUM $915M
1-Year Est. Return 209.71%
This Fund
S&P 500
This Quarter Est. Return
+64.26%
1 Year Est. Return
+209.71%
3 Year Est. Return
+484.66%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$691M
AUM Growth
+$230M
Cap. Flow
+$32M
Cap. Flow %
4.63%
Top 10 Hldgs %
98.44%
Holding
13
New
–
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$56.8M

Top Sells

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$21.9M
2
KALA icon
KALA BIO
KALA
+$2.85M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$193M 27.86%
2,346,630
– –
CRSP icon
2
CRISPR Therapeutics
CRSP
$5.23B
$132M 19.11%
2,038,763
+989,812
+94% +$56.8M
ZBIO
3
Zenas BioPharma
ZBIO
$2.05B
$109M 15.77%
4,911,539
– –
MLYS icon
4
Mineralys Therapeutics
MLYS
$2.41B
$80.2M 11.59%
2,113,933
-1,014,000
-32% -$21.9M
ORIC icon
5
Oric Pharmaceuticals
ORIC
$1.42B
$54.2M 7.84%
4,514,929
– –
DSGN icon
6
Design Therapeutics
DSGN
$915M
$49.1M 7.11%
6,526,476
– –
SPRY icon
7
ARS Pharmaceuticals
SPRY
$591M
$40.3M 5.83%
4,012,903
– –
ORKA
8
Oruka Therapeutics
ORKA
$6.31B
$8.28M 1.2%
430,330
– –
ALMS
9
Alumis Inc
ALMS
$3.23B
$7.82M 1.13%
1,959,896
– –
NKTX icon
10
Nkarta
NKTX
$167M
$6.9M 1%
3,333,333
– –
OCS icon
11
Oculis Holding
OCS
$708M
$5.67M 0.82%
322,500
– –
ENGN icon
12
enGene Therapeutics
ENGN
$122M
$5.11M 0.74%
747,750
– –
KALA icon
13
KALA BIO
KALA
$16.3M
– –
-11,979
Closed -$2.85M

Similar funds

PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
SC
Sierra Capital Miami, Florida $918M AUM 8.25% 1-Year Est. Return
SI
Symmetry Investments St Helier, Jersey $913M AUM 30.59% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $913M AUM 11.84% 1-Year Est. Return
SAA
Southeast Asset Advisors Thomasville, Georgia $913M AUM 25.32% 1-Year Est. Return
GC
Greenvale Capital London, United Kingdom $912M AUM 34.2% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
FFL
Flat Footed LLC Wilson, Wyoming $920M AUM 86.47% 1-Year Est. Return

SR One Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, SR One Capital Management held 13 positions worth $691M, up 50% from $461M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

SR One Capital Management deployed $32M of net new capital in Q3 2025, adding to 1 existing holding.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Mineralys Therapeutics, an estimated $21.9M trimmed.

  • SR One Capital Management added most to CRISPR Therapeutics in Q3 2025, an estimated $56.8M increase.
  • SR One Capital Management's biggest Q3 2025 reduction was Mineralys Therapeutics, cutting an estimated $21.9M.
  • SR One Capital Management fully exited KALA BIO in Q3 2025, selling an estimated $2.85M.
  • SR One Capital Management's ten largest holdings make up 98% of its $691M portfolio in Q3 2025.
  • SR One Capital Management opened 0 new positions and closed 1 in Q3 2025.
  • SR One Capital Management's portfolio value rose 50% quarter-over-quarter to $691M.

Based on SR One Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.